美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Eleven Biotherapeutics Inc.

3.29

+0.0000

成交量：- -

成交額：- -

市值：1.59億

市盈率：-3.37

高：3.29

開：3.29

低：3.29

收：3.29

資料載入中...

總覽公司新聞公告

公司資料

公司名字：

Eleven Biotherapeutics Inc.

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.elevenbio.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Eleven Biotherapeutics, Inc.是臨床階段生物製藥公司，擁有一個專有的蛋白質工程平台，稱為 AMP-Rx，它用於發現和發展蛋白質療法來治療眼疾。其治療方法基於在有疾病的眼睛中的細胞因子，以及它對細胞因子的結構認知和理性設計操控蛋白質調節細胞因子影響的能力。細胞因子是細胞信號分子，在可以產生重要的炎症部分上發現。該公司認為細胞因子在許多眼部疾病的基本病理機制中發揮重要作用，蛋白質療法是調節眼睛的疾病中細胞因子的影響的有效手段。該公司已利用其 AMP Rx 平台理性設計、操控和生成創新性蛋白治療候選藥物渠道把細胞因子作為靶子，並認為這是控制眼疾的關鍵。該公司現正進行針對前面的眼睛疾病，包括乾眼症疾病和過敏性結膜炎等疾病和後面的眼睛，糖尿病黃斑水腫或二甲醚和葡萄膜炎等疾病的研究和發展方案。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/EBIO/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"EBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EBIO\",,,,,undefined,":{"symbol":"EBIO","market":"US","secType":"STK","nameCN":"Eleven Biotherapeutics Inc.","latestPrice":3.29,"timestamp":1526500800000,"preClose":3.29,"halted":4,"volume":0,"delay":0,"floatShares":6754972,"shares":48390072,"eps":-0.976817,"marketStatus":"退市","change":0,"latestTime":"04-29 13:21:35 EDT","open":3.29,"high":3.29,"low":3.29,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.976817,"tradingStatus":0,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1745956800000},"marketStatusCode":2,"symbolChange":{"newSymbol":"SESN","executeDate":"2018-05-17"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.29,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"EBIO\",,,,,undefined,":{"symbol":"EBIO","floatShares":6754972,"roa":"--","roe":"--","lyrEps":0,"shares":48390072,"dividePrice":0,"high":3.29,"amplitude":0,"preClose":3.29,"low":3.29,"week52Low":0.6201,"pbRate":"6.67","week52High":3.5,"institutionHeld":0,"latestPrice":3.29,"eps":-0.976817,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.976817,"open":3.29},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.elevenbio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0719},{"period":"1month","weight":-0.0087},{"period":"3month","weight":-0.0888},{"period":"6month","weight":-0.0503},{"period":"1year","weight":0.0838},{"period":"ytd","weight":-0.0601}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Eleven Biotherapeutics, Inc.是臨床階段生物製藥公司，擁有一個專有的蛋白質工程平台，稱為 AMP-Rx，它用於發現和發展蛋白質療法來治療眼疾。其治療方法基於在有疾病的眼睛中的細胞因子，以及它對細胞因子的結構認知和理性設計操控蛋白質調節細胞因子影響的能力。細胞因子是細胞信號分子，在可以產生重要的炎症部分上發現。該公司認為細胞因子在許多眼部疾病的基本病理機制中發揮重要作用，蛋白質療法是調節眼睛的疾病中細胞因子的影響的有效手段。該公司已利用其 AMP Rx 平台理性設計、操控和生成創新性蛋白治療候選藥物渠道把細胞因子作為靶子，並認為這是控制眼疾的關鍵。該公司現正進行針對前面的眼睛疾病，包括乾眼症疾病和過敏性結膜炎等疾病和後面的眼睛，糖尿病黃斑水腫或二甲醚和葡萄膜炎等疾病的研究和發展方案。","exchange":"NASDAQ","name":"Eleven Biotherapeutics Inc.","nameEN":"Eleven Biotherapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"EBIO\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/EBIO\",params:#limit:5,,,undefined,":[{"date":"2018-05-17","symbol":"EBIO","newSymbol":"SESN","type":"symbolChange","dateTimestamp":1526529600000},{"market":"US","date":"2018-05-15","symbol":"EBIO","fiscalQuarterEnding":"2018/03","expectedEps":-0.13,"name":null,"time":"","type":"earning","dateTimestamp":1526356800000,"reportTimeType":"","actualEps":-0.11},{"market":"US","date":"2018-04-04","symbol":"EBIO","fiscalQuarterEnding":"2017/12","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1522814400000,"reportTimeType":"","actualEps":-0.22},{"market":"US","date":"2017-11-20","symbol":"EBIO","name":"Eleven Biotherapeutics Inc.","time":"","type":"earning","dateTimestamp":1511154000000,"reportTimeType":"","actualEps":-0.37},{"market":"US","date":"2017-11-14","symbol":"EBIO","fiscalQuarterEnding":"2017/09","expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1510635600000,"reportTimeType":"pre","actualEps":0.91}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"EBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"EBIO\",market:\"US\",delay:false,,,undefined,":{}}}